- Previous Close
9.810 - Open
9.890 - Bid 9.930 x --
- Ask 9.940 x --
- Day's Range
9.810 - 9.940 - 52 Week Range
7.920 - 13.300 - Volume
717,800 - Avg. Volume
2,946,024 - Market Cap (intraday)
8.747B - Beta (5Y Monthly) 0.11
- PE Ratio (TTM)
4.95 - EPS (TTM)
2.010 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 29, 2020
- 1y Target Est
12.70
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, sells, and markets pharmaceutical products in the therapeutic areas of anti-infection, endocrine and metabolic, and other diseases in the People's Republic of China. It manufactures and sells active pharmaceutical ingredients; researches and develops pharmaceutical products, and medical devices and drugs, as well as biotechnology; and provides marketing and medical consulting services. The company sells its products to hospitals and medical institutions through a network of distributors. The company's products are Kewei, Oumeining, Xinhaining, Ertongshu, and Xining. It has a strategic cooperation framework agreement with Jointown Pharmaceutical Group Co., Ltd., as well as strategic cooperative partnership with China National Accord Medicines Corporation Ltd. The company was formerly known as Yichang Changjiang Pharmaceutical Company Limited and changed its name to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. The company was incorporated in 2001 and is based in Yichang, China.
www.hec-changjiang.com4,891
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 1558.HK
View MorePerformance Overview: 1558.HK
Trailing total returns as of 3/20/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1558.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1558.HK
View MoreValuation Measures
Market Cap
8.63B
Enterprise Value
9.51B
Trailing P/E
4.88
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.45
Price/Book (mrq)
0.93
Enterprise Value/Revenue
1.60
Enterprise Value/EBITDA
4.86
Financial Highlights
Profitability and Income Statement
Profit Margin
29.74%
Return on Assets (ttm)
10.30%
Return on Equity (ttm)
19.25%
Revenue (ttm)
5.54B
Net Income Avi to Common (ttm)
1.65B
Diluted EPS (ttm)
2.010
Balance Sheet and Cash Flow
Total Cash (mrq)
1.52B
Total Debt/Equity (mrq)
27.00%
Levered Free Cash Flow (ttm)
-659.1M